Description
Triple-negative breast cancer represents a particular group of breast carcinomas defined immunohistochemically by the absence of hormone receptor expression and the absence of HER2 receptor overexpression. This group of tumors, which have the most unfavorable prognosis, does not currently benefit from any targeted treatment, and the only validated systemic therapy is chemotherapy.This is a retrospective study of the last six years conducted at the Etablissement Hspitalier Universitaire d’Oran “1er Novembre 1954” (EHUO) between 2017 and 2022 involving 59 young patients with triple-negative invasive breast carcinomas.Pathologically, infiltrating ductal carcinoma was the most predominant type, accounting for 86.4% of cases, with a majority T2 tumor size of 66.1%.Despite advances in treatment and the advent of targeted therapies, breast cancer remains the leading cause of death in women. Current clinical and histological classifications do not allow us to fully establish the prognostic and predictive parameters of response to treatment.
